{"id":70338,"date":"2026-07-21T18:52:54","date_gmt":"2026-07-21T10:52:54","guid":{"rendered":"https:\/\/flcube.com\/?p=70338"},"modified":"2026-07-21T18:52:55","modified_gmt":"2026-07-21T10:52:55","slug":"akeso-biopharma-launches-greater-bay-area-charitable-program-to-provide-free-ivonescimab-to-hong-kong-lung-cancer-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70338","title":{"rendered":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Akeso Biopharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>) announced the signing of the <strong>Greater Bay Area Innovative Drug Charitable Donation Program<\/strong> with Hong Kong-based <strong>AccessRx<\/strong>, establishing a pioneering public welfare initiative to provide <strong>free, world-leading immunotherapy treatments<\/strong> to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the <strong>clinical screening phase<\/strong> for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the <strong>Guangdong-Hong Kong-Macao Greater Bay Area<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-program-structure-amp-implementation\" class=\"wp-block-heading\">Program Structure &amp; Implementation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partnership<\/strong><\/td><td>Akeso Biopharma + AccessRx (Hong Kong)<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Guangdong-Hong Kong-Macao Greater Bay Area<\/td><\/tr><tr><td><strong>Current Status<\/strong><\/td><td>Clinical screening phase for first patient cohort<\/td><\/tr><tr><td><strong>Delivery Mechanism<\/strong><\/td><td>Hong Kong Named Patient Program (NPP)<\/td><\/tr><tr><td><strong>Treatment Setting<\/strong><\/td><td>Hong Kong public hospitals<\/td><\/tr><tr><td><strong>Patient Eligibility<\/strong><\/td><td>Financially disadvantaged lung cancer patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-ivonescimab-yidafang\" class=\"wp-block-heading\">Drug Profile: Ivonescimab (Yidafang)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> First-in-class <strong>PD-1\/VEGF bispecific tumor immunotherapy<\/strong><\/li>\n\n\n\n<li><strong>Development:<\/strong> Independently developed by Akeso Biopharma<\/li>\n\n\n\n<li><strong>Brand Name:<\/strong> Yidafang<\/li>\n\n\n\n<li><strong>Mainland China Approvals:<\/strong><\/li>\n\n\n\n<li>Locally advanced or metastatic non-squamous NSCLC progressing on EGFR-TKI therapy<\/li>\n\n\n\n<li>First-line treatment of advanced NSCLC with PD-L1-positive expression<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual targeting of PD-1 and VEGF pathways for enhanced anti-tumor activity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-hong-kong-named-patient-program-npp-framework\" class=\"wp-block-heading\">Hong Kong Named Patient Program (NPP) Framework<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Purpose:<\/strong> Special access mechanism for patients in urgent medical need<\/li>\n\n\n\n<li><strong>Eligibility:<\/strong> Drugs approved overseas but not yet registered in Hong Kong<\/li>\n\n\n\n<li><strong>Requirements:<\/strong> Must meet legal and ethical standards<\/li>\n\n\n\n<li><strong>Clinical Oversight:<\/strong> Prescribed by qualified clinicians in public hospital settings<\/li>\n\n\n\n<li><strong>Regulatory Context:<\/strong> Bridges access gap while formal registration process continues<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-amp-industry-impact\" class=\"wp-block-heading\">Strategic Significance &amp; Industry Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access Strategy:<\/strong> Accelerates patient access while pursuing formal Hong Kong regulatory approval<\/li>\n\n\n\n<li><strong>Corporate Social Responsibility:<\/strong> Demonstrates commitment to equitable healthcare access across Greater Bay Area<\/li>\n\n\n\n<li><strong>Regional Integration:<\/strong> Supports cross-border healthcare collaboration within national development strategy<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Positions Akeso as both innovator and accessibility advocate in premium oncology segment<\/li>\n\n\n\n<li><strong>Precedent Setting:<\/strong> Establishes model for future charitable programs involving innovative biologics in Hong Kong<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The charitable donation program represents Akeso&#8217;s dual commitment to innovation and accessibility, ensuring that cutting-edge immunotherapy reaches patients regardless of financial circumstances while building goodwill ahead of potential commercial launch in Hong Kong.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding program implementation, regulatory pathways, and market access strategies. Actual outcomes may vary based on regulatory decisions, patient enrollment, and program execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70339,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[360,3582,850],"class_list":["post-70338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-akeso-biopharma","tag-great-bay-bio","tag-hkg-9926"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70338\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients\" \/>\n<meta property=\"og:description\" content=\"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70338\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-21T10:52:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-21T10:52:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients\",\"datePublished\":\"2026-07-21T10:52:54+00:00\",\"dateModified\":\"2026-07-21T10:52:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2101.webp\",\"keywords\":[\"Akeso Biopharma\",\"Great Bay Bio\",\"HKG: 9926\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70338#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70338\",\"name\":\"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2101.webp\",\"datePublished\":\"2026-07-21T10:52:54+00:00\",\"dateModified\":\"2026-07-21T10:52:55+00:00\",\"description\":\"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70338\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70338#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients - Insight, China&#039;s Pharmaceutical Industry","description":"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70338","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients","og_description":"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.","og_url":"https:\/\/flcube.com\/?p=70338","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-21T10:52:54+00:00","article_modified_time":"2026-07-21T10:52:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70338#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70338"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients","datePublished":"2026-07-21T10:52:54+00:00","dateModified":"2026-07-21T10:52:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70338"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","keywords":["Akeso Biopharma","Great Bay Bio","HKG: 9926"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70338#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70338","url":"https:\/\/flcube.com\/?p=70338","name":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70338#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","datePublished":"2026-07-21T10:52:54+00:00","dateModified":"2026-07-21T10:52:55+00:00","description":"Akeso Biopharma (HKG: 9926) announced the signing of the Greater Bay Area Innovative Drug Charitable Donation Program with Hong Kong-based AccessRx, establishing a pioneering public welfare initiative to provide free, world-leading immunotherapy treatments to Hong Kong oncology patients facing financial barriers to medication access. The program has already entered the clinical screening phase for its first cohort of patients and aims to set a benchmark for pharmaceutical industry collaboration in the Guangdong-Hong Kong-Macao Greater Bay Area.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70338#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70338"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70338#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","width":1080,"height":608,"caption":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70338#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70338"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70338\/revisions"}],"predecessor-version":[{"id":70340,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70338\/revisions\/70340"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70339"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}